Lorlatinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-small cell lung cancer that can be removed with surgery (stage IB to IIIB).
- Your cancer must have the ALK gene change (ALK-positive), confirmed by a local lab.
- You must be in good enough health to have surgery and take the study drug (ECOG score 0 or 1).
- You cannot have had any prior cancer treatment for this lung cancer, such as chemotherapy or immunotherapy.
- Women who can become pregnant must use birth control; men must use barrier contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests the drug lorlatinib given before surgery to shrink tumors in people with a specific genetic change (ALK rearrangement) in their lung cancer. It may help make surgery more effective.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.